These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32744731)

  • 1. Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies.
    Jeng MY; Dutta R; Tan IT; Zhang TY; Mannis GN
    Am J Hematol; 2020 Nov; 95(11):E305-E308. PubMed ID: 32744731
    [No Abstract]   [Full Text] [Related]  

  • 2. New drugs approved for acute myeloid leukaemia in 2018.
    Kucukyurt S; Eskazan AE
    Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Tremblay D; Feld J; Dougherty M; Czaplinska T; Sanchez G; Kremyanskaya M; Bar-Natan M; Shih AH; Keyzner A; Mascarenhas J
    Leuk Res; 2020 Nov; 98():106456. PubMed ID: 33002673
    [No Abstract]   [Full Text] [Related]  

  • 4. Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Fischer K; Al-Sawaf O; Fink AM; Dixon M; Bahlo J; Warburton S; Kipps TJ; Weinkove R; Robinson S; Seiler T; Opat S; Owen C; López J; Humphrey K; Humerickhouse R; Tausch E; Frenzel L; Eichhorst B; Wendtner CM; Stilgenbauer S; Langerak AW; van Dongen JJM; Böttcher S; Ritgen M; Goede V; Mobasher M; Hallek M
    Blood; 2017 May; 129(19):2702-2705. PubMed ID: 28325865
    [No Abstract]   [Full Text] [Related]  

  • 5. CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
    Fakhri B; Andreadis C
    Oncology (Williston Park); 2019 Nov; 33(11):. PubMed ID: 31769861
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax with decitabine or azacitidine for AML.
    Das M
    Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
    Arslan S; Zhang J; Dhakal P; Moran J; Naidoo N; Lombardi J; Pullarkat V; Stein AS; Marcucci G; Yaghmour G; Bhatt VR; Fathi AT; Aldoss I
    Am J Hematol; 2021 Mar; 96(3):E59-E63. PubMed ID: 33227142
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.
    Begna KH; Gangat N; Al-Kali A; Litzow MR; Hogan WJ; Patnaik MM; Pardanani A; Hook CC; Wolanskyj AP; Elliott MA; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2021 Apr; 96(4):E108-E111. PubMed ID: 33527451
    [No Abstract]   [Full Text] [Related]  

  • 9. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
    Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
    Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
    Daraskevicius J; Everatt V; Vaitekenaite V; Ringeleviciute U; Maneikis K; Zucenka A
    Leuk Res; 2021 Dec; 111():106692. PubMed ID: 34438121
    [No Abstract]   [Full Text] [Related]  

  • 11. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
    Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
    Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
    Liao PW; Wang RC; Chen TC; Teng CJ
    Ann Hematol; 2021 May; 100(5):1333-1334. PubMed ID: 33439305
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
    Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
    Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
    [No Abstract]   [Full Text] [Related]  

  • 15. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.
    Aldoss I; Zhang J; Pillai R; Shouse G; Sanchez JF; Mei M; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Br J Haematol; 2019 Oct; 187(2):e45-e48. PubMed ID: 31441045
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
    Jiang H; Lwin T; Zhao X; Ren Y; Li G; Moscinski L; Shah B; Tao J
    Br J Haematol; 2019 Jan; 184(2):298-302. PubMed ID: 29383700
    [No Abstract]   [Full Text] [Related]  

  • 17. Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Cheng FM; Tien JZ; Chen TT; Yeh SP; Lin CC
    Ann Hematol; 2020 Sep; 99(9):2193-2195. PubMed ID: 32621180
    [No Abstract]   [Full Text] [Related]  

  • 18. Is the overall survival for older adults with AML finally improving?
    Lancet JE
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
    Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
    Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
    [No Abstract]   [Full Text] [Related]  

  • 20. Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Othman TA; Mei M; Zhang J; Aldoss I; Stein A; Forman SJ; Marcucci G; Pullarkat V
    Am J Hematol; 2021 May; 96(5):E140-E143. PubMed ID: 33524204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.